A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin.
Ophthalmic Res
; 66(1): 1030-1043, 2023.
Article
in En
| MEDLINE
| ID: mdl-37257422
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Glioblastoma
Type of study:
Clinical_trials
Limits:
Adult
/
Humans
Language:
En
Journal:
Ophthalmic Res
Year:
2023
Document type:
Article
Affiliation country: